Treatment of central sleep apnoea and Cheyne Stokes respiration in patients with heart failure: <br>nasal high-flow oxygen therapy?<br>
Phase 2
Completed
- Conditions
- sleep disorders breathingcentral sleep apnoea1003871610019280
- Registration Number
- NL-OMON47575
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 10
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
• Moderate to severe central sleep apnoea (CSA)/Cheyne Stokes respiration (apnoea/hypopnoea index>15), in which CSA is defined when at least 50% of the apnoea*s are central apnoea*s
• Heart failure diagnosed by cardiologist
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
• Other diseases affecting respiration during sleep (COPD GOLD 3 or 4, neuromuscular disorders, thorax cage deformities)
• At the moment of the inclusion, the patient does not have a therapy to treat the CSA, such as CPAP, oxygen, BiPAP or acetazolamide.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The aim of this study is to investigate whether patients with CHF and CSA would<br /><br>benefit from nHFT with and without oxygen in terms of an improved AHI during<br /><br>sleep while on nHFT, measured after 4 weeks of home nHFT treatment, as compared<br /><br>to the baseline AHI during spontaneous nocturnal breathing. </p><br>
- Secondary Outcome Measures
Name Time Method